A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Dihomo-gamma linolenic acid (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms ADvance
  • Sponsors DS Biopharma
  • Most Recent Events

    • 06 Jan 2017 Status changed from not yet recruiting to recruiting, as per a DS Biopharma media release.
    • 18 Oct 2016 Planned number of patients changed from 240 to 300.
    • 18 Oct 2016 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top